• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    7/21/22 5:54:07 PM ET
    $BPTS
    $CLRB
    $DCTH
    $HNGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPTS alert in real time by email

    Gainers

    • Hanger (NYSE:HNGR) stock moved upwards by 27.1% to $18.75 during Thursday's after-market session. The company's market cap stands at $731.7 million.
    • Biophytis (NASDAQ:BPTS) stock rose 13.92% to $0.99. The company's market cap stands at $16.2 million.
    • IsoPlexis (NASDAQ:ISO) shares rose 12.31% to $3.74. The company's market cap stands at $146.1 million.
    • Delcath Systems (NASDAQ:DCTH) shares increased by 11.13% to $4.89. The company's market cap stands at $38.6 million.
    • Plus Therapeutics (NASDAQ:PSTV) shares moved upwards by 10.0% to $0.55. The company's market cap stands at $12.2 million. The company's, Q2 earnings came out today.
    • Vallon Pharmaceuticals (NASDAQ:VLON) stock increased by 9.6% to $0.55. The market value of their outstanding shares is at $5.8 million.

    Losers

    • Cellectar Biosciences (NASDAQ:CLRB) stock decreased by 20.8% to $0.49 during Thursday's after-market session. Trading volume for this security closed at 125.5K, accounting for 91.1% of its average full-day volume over the last 100 days. The company's market cap stands at $30.1 million.
    • Intuitive Surgical (NASDAQ:ISRG) stock declined by 12.97% to $195.6. This security traded at a volume of 364.6K shares come close, making up 16.8% of its average volume over the last 100 days. The company's market cap stands at $70.2 billion. As per the press release, Q2 earnings came out today.
    • Pluristem Therapeutics (NASDAQ:PSTI) stock fell 7.41% to $1.0. The market value of their outstanding shares is at $32.3 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) shares decreased by 6.69% to $0.22. At the close, ThermoGenesis Holdings's trading volume reached 50.5K shares. This is 2.7% of its average volume over the last 100 days. The company's market cap stands at $6.8 million.
    • Idera Pharmaceuticals (NASDAQ:IDRA) stock declined by 5.88% to $0.39. The market value of their outstanding shares is at $20.6 million.
    • Purple Biotech (NASDAQ:PPBT) stock fell 5.63% to $2.35. The market value of their outstanding shares is at $42.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BPTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BPTS
    $CLRB
    $DCTH
    $HNGR

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    3/11/2026$590.00Neutral → Buy
    Citigroup
    Cellectar Biosciences Inc.
    $CLRB
    3/10/2026$10.00Hold → Buy
    Maxim Group
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Intuitive Surgical Inc.
    $ISRG
    1/27/2026$660.00Buy
    TD Cowen
    Intuitive Surgical Inc.
    $ISRG
    12/11/2025$635.00Buy → Neutral
    Citigroup
    PLUS THERAPEUTICS Inc.
    $PSTV
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    Intuitive Surgical Inc.
    $ISRG
    7/23/2025Buy → Hold
    Erste Group
    Intuitive Surgical Inc.
    $ISRG
    6/9/2025$440.00Hold → Sell
    Deutsche Bank
    More analyst ratings

    $BPTS
    $CLRB
    $DCTH
    $HNGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lankry Shai S

    3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)

    3/27/26 11:38:07 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Gagnon Robert E.

    3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)

    3/18/26 6:06:33 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Medical Officer Curet Myriam exercised 105 shares at a strike of $229.39 and sold $51,865 worth of shares (105 units at $493.95) (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    3/11/26 1:46:06 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    $BPTS
    $CLRB
    $DCTH
    $HNGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

    HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of diagnostics industry veteran Ron Andrews to its Board of Directors. "Ron Andrews brings an extensive wealth of diagnostics experience to the Plus board room developed over multiple decades in the industry," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "He will make an immediate impact on the Company as we scale CNSide, first in the U.S. and then globally. Furthermore, his bre

    3/26/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform

    Collaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needs AI-driven development strategy designed to significantly accelerate discovery timelines and enhance molecule quality for drug candidates targeting solid tumors REHOVOT, Israel and BOSTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced a collaboration with Converge Bio, a company known for its leading AI platform for drug di

    3/25/26 8:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems

    SAN CARLOS, Calif., March 24, 2026 /PRNewswire/ -- Sonder Capital, a healthcare venture capital firm investing in companies revolutionizing the standard of care, today announced the closing of its second fund, Futures II. The fund includes participation from Mayo Clinic and Sutter Health, reflecting their collective interest in innovative technologies that have the potential to advance the future of patient care by enhancing access, improving quality and transforming the overall patient experience."Through our second fund we'll continue enabling the next wave of companies and he

    3/24/26 11:03:00 AM ET
    $ISRG
    $PRCT
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $BPTS
    $CLRB
    $DCTH
    $HNGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Pennell Sandra bought $50,018 worth of shares (5,533 units at $9.04), increasing direct ownership by 8% to 77,018 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/6/26 4:22:21 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Michel Gerard J bought $100,309 worth of shares (11,200 units at $8.96), increasing direct ownership by 3% to 342,034 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/3/26 4:15:22 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Director Sylvester John Richard bought $38,992 worth of shares (4,386 units at $8.89), increasing direct ownership by 42% to 14,936 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    11/25/25 4:15:07 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $BPTS
    $CLRB
    $DCTH
    $HNGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intuitive Surgical upgraded by Citigroup with a new price target

    Citigroup upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $590.00

    3/11/26 8:28:54 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Cellectar Biosciences upgraded by Maxim Group with a new price target

    Maxim Group upgraded Cellectar Biosciences from Hold to Buy and set a new price target of $10.00

    3/10/26 8:36:07 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $BPTS
    $CLRB
    $DCTH
    $HNGR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Intuitive Surgical Inc.

    SCHEDULE 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)

    3/27/26 9:55:20 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Leadership Update

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    3/26/26 8:33:06 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Purple Biotech Ltd.

    6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)

    3/25/26 8:05:24 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTS
    $CLRB
    $DCTH
    $HNGR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    10/2/24 4:43:10 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

    5/23/24 10:32:08 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    1/23/24 4:36:46 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $BPTS
    $CLRB
    $DCTH
    $HNGR
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

    HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of diagnostics industry veteran Ron Andrews to its Board of Directors. "Ron Andrews brings an extensive wealth of diagnostics experience to the Plus board room developed over multiple decades in the industry," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "He will make an immediate impact on the Company as we scale CNSide, first in the U.S. and then globally. Furthermore, his bre

    3/26/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Purple Biotech Announces CEO Transition

    Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing next-generation cancer therapies, today announced that Gil Efron, Chief Executive Officer, will step down from his role as CEO effective August 2026. Mr. Efron will remain actively involved with the Company, transitioning to lead corporate development and continuing as a member of the Board of Directors. In this new capacity, he will focus on identifying strategic initiatives, partnerships, and support the Company's financing activities as needed

    3/13/26 8:04:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intel Appoints Dr. Craig H. Barratt to Board of Directors

    Intel Corporation (NASDAQ:INTC) today announced that Craig H. Barratt, Ph.D., 63, has been appointed to its board of directors, effective immediately. Dr. Barratt will serve as an independent director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110908011/en/Dr. Craig H. Barratt joins Intel's board as an independent director. "Craig is a highly accomplished technology leader with a proven ability to innovate, scale, and transform businesses," said Lip-Bu Tan, Intel CEO. "He is a seasoned semiconductor executive with experience at multiple leading-edge technology companies, which will be invaluable as we continue to execute

    11/10/25 6:21:00 PM ET
    $ALAB
    $INTC
    $ISRG
    Semiconductors
    Technology
    Industrial Specialties
    Health Care

    $BPTS
    $CLRB
    $DCTH
    $HNGR
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

    HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal fluid (CSF) assay. The cost-of-care analysis suggests that earlier LM diagnosis and therapeutic management enabled by CNSide may reduce overall LM-related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention, improved treatment precisio

    3/19/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

    On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the year ended December 31

    3/4/26 7:15:00 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

    Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $19.0 million and $78.8 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.7 million and $6.4 million, respectively Gro

    2/26/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $BPTS
    $CLRB
    $DCTH
    $HNGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/15/24 10:33:51 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 9:46:56 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Delcath Systems Inc.

    SC 13G/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 7:02:01 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care